Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DI81LW
|
|||
Drug Name |
UNC569
|
|||
Synonyms |
unc569; 1350547-65-7; 1-[(Trans-4-Aminocyclohexyl)methyl]-N-Butyl-3-(4-Fluorophenyl)-1h-Pyrazolo[3,4-D]pyrimidin-6-Amine; CHEMBL2036808; 1-(((1r,4r)-4-aminocyclohexyl)methyl)-N-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine; SCHEMBL12185720; SCHEMBL14755115; SCHEMBL17173901; SCHEMBL17178092; UNC 569; UNC-569; BDBM336260; UNC-569;UNC 569; BCP27883; EX-A2464; BDBM50384576; ZINC101508966; ZINC254077925; NCGC00386692-01; AS-35154; US9744172, Compound UNC00000569A; Q27458844; 1-[(4-aminocyclohexyl)methyl]-N-butyl-3-(4-fluorophenyl)pyrazolo[3,4-d]pyrimidin-6-amine; 1-((4-aminocyclohexyl)methyl)-N-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine; CKJ; rel-1-(((1r,4r)-4-Aminocyclohexyl)methyl)-N-butyl-3-(4-fluorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C91.0] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C22H29FN6
|
|||
Canonical SMILES |
CCCCNC1=NC=C2C(=NN(C2=N1)CC3CCC(CC3)N)C4=CC=C(C=C4)F
|
|||
InChI |
1S/C22H29FN6/c1-2-3-12-25-22-26-13-19-20(16-6-8-17(23)9-7-16)28-29(21(19)27-22)14-15-4-10-18(24)11-5-15/h6-9,13,15,18H,2-5,10-12,14,24H2,1H3,(H,25,26,27)
|
|||
InChIKey |
OGEBRHQLRGFBNV-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tyrosine-protein kinase Mer (MERTK) | Target Info | Inhibitor | [1] |
NetPath Pathway | TSH Signaling Pathway | |||
Reactome | Cell surface interactions at the vascular wall | |||
WikiPathways | Cell surface interactions at the vascular wall |
References | Top | |||
---|---|---|---|---|
REF 1 | UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013 Nov;12(11):2367-77. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.